BR112013016917A2 - ligantes que ligam receptor de tgf-beta ii. - Google Patents

ligantes que ligam receptor de tgf-beta ii.

Info

Publication number: BR112013016917A2
Authority: BR; Brazil
Prior art keywords: tgf; receptor binding; beta receptor; binding binders; binders
Prior art date: 2011-01-06

Application number

BR112013016917A

Other languages

English (en)

Inventor

Beaton Andrew

Dimech Caroline

Franz Ertl Peter

Mcadam Ruth

Karen Ford Susannah

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-06

Filing date

2012-01-04

Publication date

2017-04-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45444622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013016917(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-01-04 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2017-04-04 Publication of BR112013016917A2 publication Critical patent/BR112013016917A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)

BR112013016917A 2011-01-06 2012-01-04 ligantes que ligam receptor de tgf-beta ii. BR112013016917A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161430235P	2011-01-06	2011-01-06
PCT/EP2012/050061 WO2012093125A1 (en)	2011-01-06	2012-01-04	Ligands that bind tgf-beta receptor ii

Publications (1)

Publication Number	Publication Date
BR112013016917A2 true BR112013016917A2 (pt)	2017-04-04

Family

ID=45444622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112013016917A BR112013016917A2 (pt)	2011-01-06	2012-01-04	ligantes que ligam receptor de tgf-beta ii.

Country Status (21)

Country	Link
US (3)	US9150651B2 (pt)
EP (1)	EP2661449B1 (pt)
JP (2)	JP6062375B2 (pt)
KR (1)	KR101886898B1 (pt)
CN (1)	CN103443126B (pt)
AU (1)	AU2016203609A1 (pt)
BR (1)	BR112013016917A2 (pt)
CA (1)	CA2823104A1 (pt)
CL (1)	CL2013001975A1 (pt)
CO (1)	CO6811807A2 (pt)
CR (1)	CR20130376A (pt)
DO (1)	DOP2013000162A (pt)
EA (1)	EA201391012A1 (pt)
ES (1)	ES2627299T3 (pt)
IL (1)	IL227254A0 (pt)
MA (1)	MA34820B1 (pt)
MX (1)	MX2013007936A (pt)
PE (1)	PE20140982A1 (pt)
SG (1)	SG191762A1 (pt)
WO (1)	WO2012093125A1 (pt)
ZA (1)	ZA201304726B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2627299T3 (es) *	2011-01-06	2017-07-27	Glaxo Group Limited	Ligandos que se unen al receptor II del TGF-beta
DK2723769T4 (da) *	2011-06-23	2022-09-05	Ablynx Nv	Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
CA2902910A1 (en) *	2013-03-15	2014-09-25	Ac Immune S.A.	Anti-tau antibodies and methods of use
CN116655801A (zh)	2013-08-22	2023-08-29	阿塞勒隆制药公司	TGF-β受体II型变体及其用途
DK3685848T3 (da)	2013-11-21	2021-12-13	Brigham & Womens Hospital Inc	Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
MX2016008540A (es) *	2014-01-15	2016-09-26	Hoffmann La Roche	Variantes de region fc con propiedades de union al receptor fc neonatal (fcrn).
CN114470207B (zh)	2014-08-01	2023-09-19	布里格姆及妇女医院股份有限公司	与肺动脉高压的治疗有关的组合物和方法
MY180297A (en) *	2015-06-24	2020-11-27	Hoffmann La Roche	Anti-transferrin receptor antibodies with tailored affinity
CN116327952A (zh)	2015-08-04	2023-06-27	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
US20190023809A1 (en) *	2015-09-03	2019-01-24	The Children's Mercy Hospital	Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI747843B (zh)	2015-10-02	2021-12-01	瑞士商赫孚孟拉羅股份公司	雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
US11142569B2 (en) *	2015-11-13	2021-10-12	Ablynx N.V.	Serum albumin-binding immunoglobulin variable domains
US20190119387A1 (en)	2016-04-05	2019-04-25	Glaxosmithkline Intellectual Property Development Limited	Inhibition of tgfbeta in immunotherapy
EP4241848A3 (en)	2017-05-04	2023-11-01	Acceleron Pharma Inc.	Tgf-beta receptor type ii fusion proteins and uses thereof
GB201807693D0 (en) *	2018-05-11	2018-06-27	Autolus Ltd	Cell
JP7542799B2 (ja) *	2018-07-04	2024-09-02	京都府公立大学法人	眼組織の線維化抑制用組成物
CA3165605A1 (en)	2019-12-24	2021-07-01	Merus N.V.	Tgf-beta-rii binding proteins
KR102314157B1 (ko) *	2020-01-10	2021-10-19	주식회사 뉴클릭스바이오	TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
US20220144956A1 (en) *	2020-11-06	2022-05-12	Xencor, Inc.	HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
EP4291227A2 (en)	2021-02-15	2023-12-20	Takeda Pharmaceutical Company Limited	Cell therapy compositions and methods for modulating tgf-b signaling

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994026087A2 (en)	1993-05-14	1994-11-24	Connor Kim C O	Recombinant protein production and insect cell culture and process
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
JP2001206899A (ja) *	1999-11-18	2001-07-31	Japan Tobacco Inc	ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20050053973A1 (en)	2001-04-26	2005-03-10	Avidia Research Institute	Novel proteins with targeted binding
US20050089932A1 (en)	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
DK1399484T3 (da)	2001-06-28	2010-11-08	Domantis Ltd	Dobbelt-specifik ligand og anvendelse af denne
US20080108560A1 (en)	2002-03-05	2008-05-08	Eli Lilly And Company	Heterologous G-Csf Fusion Proteins
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
DK1517921T3 (da)	2002-06-28	2006-10-09	Domantis Ltd	Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
WO2004041865A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Stabilized single domain antibodies
AU2003290330A1 (en)	2002-12-27	2004-07-22	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2525120C (en)	2003-05-14	2013-04-30	Domantis Limited	A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
DK1639011T3 (da)	2003-06-30	2009-02-16	Domantis Ltd	Pegylerede enkelt-domæne antistoffer (dAb)
CA2543360A1 (en)	2003-10-24	2005-05-06	Joost A. Kolkman	Ldl receptor class a and egf domain monomers and multimers
CA2554089C (en)	2004-02-09	2013-10-22	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005093074A1 (en)	2004-03-24	2005-10-06	Domantis Limited	Gas1 universal leader
GB0418651D0 (en)	2004-08-20	2004-09-22	Medical Res Council	Method
US20070012251A1 (en)	2005-07-07	2007-01-18	Martin Zucker	Seal arrangement with corrosion barrier and method
BRPI0710572A2 (pt)	2006-01-24	2013-01-08	Domantis Ltd	ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
GB0724331D0 (en)	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
JO3096B1 (ar) *	2008-11-07	2017-03-15	Imclone Llc	الأجسام المضادة لمستقبل ii مضاد tgfb
CA2768981A1 (en) *	2009-07-29	2011-02-03	Rudolf Maria De Wildt	Ligands that bind tgf-beta receptor rii
CA2780221A1 (en) *	2009-11-04	2011-05-12	Fabrus Llc	Methods for affinity maturation-based antibody optimization
ES2627299T3 (es) *	2011-01-06	2017-07-27	Glaxo Group Limited	Ligandos que se unen al receptor II del TGF-beta

2012
- 2012-01-04 ES ES12700019.8T patent/ES2627299T3/es active Active
- 2012-01-04 BR BR112013016917A patent/BR112013016917A2/pt not_active Application Discontinuation
- 2012-01-04 CA CA2823104A patent/CA2823104A1/en not_active Abandoned
- 2012-01-04 US US13/978,228 patent/US9150651B2/en not_active Expired - Fee Related
- 2012-01-04 MA MA36101A patent/MA34820B1/fr unknown
- 2012-01-04 MX MX2013007936A patent/MX2013007936A/es not_active Application Discontinuation
- 2012-01-04 WO PCT/EP2012/050061 patent/WO2012093125A1/en active Application Filing
- 2012-01-04 JP JP2013547846A patent/JP6062375B2/ja not_active Expired - Fee Related
- 2012-01-04 KR KR1020137020615A patent/KR101886898B1/ko active IP Right Grant
- 2012-01-04 SG SG2013049663A patent/SG191762A1/en unknown
- 2012-01-04 PE PE2013001516A patent/PE20140982A1/es not_active Application Discontinuation
- 2012-01-04 CN CN201280012010.6A patent/CN103443126B/zh not_active Expired - Fee Related
- 2012-01-04 EA EA201391012A patent/EA201391012A1/ru unknown
- 2012-01-04 EP EP12700019.8A patent/EP2661449B1/en active Active
2013
- 2013-06-25 ZA ZA2013/04726A patent/ZA201304726B/en unknown
- 2013-06-27 IL IL227254A patent/IL227254A0/en unknown
- 2013-07-03 DO DO2013000162A patent/DOP2013000162A/es unknown
- 2013-07-05 CL CL2013001975A patent/CL2013001975A1/es unknown
- 2013-07-16 CO CO13168686A patent/CO6811807A2/es unknown
- 2013-08-05 CR CR20130376A patent/CR20130376A/es unknown
2015
- 2015-09-02 US US14/843,250 patent/US9850307B2/en not_active Expired - Fee Related
2016
- 2016-05-31 AU AU2016203609A patent/AU2016203609A1/en not_active Abandoned
- 2016-10-20 JP JP2016205978A patent/JP6453289B2/ja not_active Expired - Fee Related
2017
- 2017-11-21 US US15/818,861 patent/US20180086835A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2013007936A (es)	2013-08-09
CL2013001975A1 (es)	2014-03-07
KR101886898B1 (ko)	2018-08-08
ZA201304726B (en)	2014-03-26
AU2016203609A1 (en)	2016-06-16
JP6062375B2 (ja)	2017-01-18
US20150361176A1 (en)	2015-12-17
JP2017051191A (ja)	2017-03-16
JP2014504866A (ja)	2014-02-27
US9850307B2 (en)	2017-12-26
NZ612839A (en)	2014-09-26
PE20140982A1 (es)	2014-08-22
JP6453289B2 (ja)	2019-01-16
ES2627299T3 (es)	2017-07-27
CO6811807A2 (es)	2013-12-16
SG191762A1 (en)	2013-08-30
IL227254A0 (en)	2013-09-30
KR20140036146A (ko)	2014-03-25
CR20130376A (es)	2013-11-29
CA2823104A1 (en)	2012-07-12
CN103443126A (zh)	2013-12-11
DOP2013000162A (es)	2014-01-15
CN103443126B (zh)	2016-11-23
WO2012093125A1 (en)	2012-07-12
US9150651B2 (en)	2015-10-06
AU2012204867A1 (en)	2013-07-25
EP2661449A1 (en)	2013-11-13
US20130302335A1 (en)	2013-11-14
MA34820B1 (fr)	2014-01-02
AU2012204867B2 (en)	2016-03-10
EP2661449B1 (en)	2017-03-22
US20180086835A1 (en)	2018-03-29
EA201391012A1 (ru)	2014-01-30
AU2012204867A8 (en)	2016-03-24

Publication	Publication Date	Title
BR112013016917A2 (pt)	2017-04-04	ligantes que ligam receptor de tgf-beta ii.
LTC2504364I2 (lt)	2020-10-12	Tiksliniai surišantys agentai prieš B7-H1
DK2714735T3 (da)	2021-10-18	Antistoffer, der er specifikke for TGF-beta
BR112014028222A2 (pt)	2017-06-27	conjugados vinculadores auto-estabilizantes.
BR112014022692A2 (pt)	2017-06-20	Molécula de ligação de antígeno multiespecífica
BR112013024256A2 (pt)	2018-06-19	veículo.
BRPI1013789A2 (pt)	2016-04-12	sistema de arquivo.
DK2651436T3 (da)	2016-06-20	Mycobakterie antigen sammensætning.
BR112013030352A2 (pt)	2017-08-01	proteínas de ligação do receptor fc
BRPI1014262A2 (pt)	2017-05-23	anticorpos específicos para caderina-17
BR112013021602A2 (pt)	2019-09-24	derivados de heteroarila como moduladores de nachr alfa7.
BR112014018627A2 (pt)	2017-06-20	Transferência de arquivo usando xml
IT1398984B1 (it)	2013-03-28	Dispositivo blocco-porta perfezionato.
BR112013013126A2 (pt)	2016-08-23	atenuador de imapcto para veículos
DE112011101302A5 (de)	2013-01-31	Kupplungsbetätigungssystem
BRPI0924281A2 (pt)	2016-01-26	dispositivo de amortecimento para componentes planos
BR112012018744A2 (pt)	2018-06-05	mecanismo de força
DE112011104099A5 (de)	2013-11-28	Zusammentragmaschine
HK1171162A2 (en)	2013-03-15	Loose-leaf binder
DE112012002820A5 (de)	2014-04-17	Hebelsystem
FI20095534A0 (fi)	2009-05-13	Side, esimerkiksi suksiside
HK1171616A2 (en)	2013-03-28	Loose-leaf binder
TH108504B (th)	2011-06-09	ถาดใส่คลิบ
IT1394489B1 (it)	2012-07-05	Gruppo di legatura.
FI20090295A0 (fi)	2009-08-11	Sideaine

Legal Events

Date	Code	Title	Description
2018-04-03	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-09	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.
2020-10-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-11-03	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-01-26	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2021-02-23	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements